Mercedes
Iñarrairaegui Bastarrica
Consultora Médica
Hospital Universitario de Donostia
San Sebastián, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Donostia (6)
2022
-
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
Journal for immunotherapy of cancer, Vol. 10, Núm. 11
2019
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672
-
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
Hepatology, Vol. 70, Núm. 2, pp. 547-562
2017
-
Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers
Medicina Clinica, Vol. 149, Núm. 2, pp. 61-71
-
Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
Oncotarget, Vol. 8, Núm. 61, pp. 103077-103086
2016
-
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib
Liver International, Vol. 36, Núm. 8, pp. 1206-1212